Sanofi Consumer Healthcare India Limited has informed the Exchange about the transcript of the Institutional Investor Meet held on Tuesday, 24th March 2026

Sanofi Consumer Healthcare India (maker of Allegra, Combiflam, Avil, DePURA) held its first investor meet since the demerger and listing. The company reported a turnover of around ₹880 crore, profit from operations of ~37%, and ROCE of 62.5%, with FY25 performance showing revenue up 21%, operating profit up 13% and PAT up 33%. Management outlined a growth strategy built on three pillars: doubling HCP (healthcare professional) reach and direct retail coverage in 2026, scaling consumer engagement and brand investment, and pursuing product innovation. The CFO noted that domestic sales grew 22% including recall impact, or 11% on a like-for-like basis, and confirmed that all recalled products are back in the market. Management indicated openness to inorganic opportunities with parent Opella, highlighted India as a key growth geography, and said the OTC policy could unlock direct consumer communication for brands like Allegra.